ChemoCentryx price target lowered to $11 from $19 at Citigroup Citigroup lowered its price target for ChemoCentryx after vercirnon in Crohn’s disease did not meet the primary endpoint. Citi keeps a Buy rating on the stock, saying the company's CCX140 program has a high risk/reward.
News For CCXI From The Last 14 Days
Check below for free stories on CCXI the last two weeks.
On The Fly: Analyst Downgrade Summary Today's noteworthy downgrades include: AT&T (T) downgraded to Neutral from Overweight at JPMorgan... Bank of Kentucky (BKYF) downgraded to Neutral from Outperform at RW Baird... ChemoCentryx (CCXI) downgraded to Neutral from Buy at Citigroup... Citigroup (C) downgraded to Neutral from Conviction Buy at Goldman... eBay (EBAY) downgraded to Equal Weight from Overweight at Evercore... Flextronics (FLEX) downgraded to Sell from Neutral at Goldman... Old Line Bancshares (OLBK) downgraded to Neutral from Outperform at RW Baird... Fidus Investment (FDUS) downgraded to Perform from Outperform at Oppenheimer... New York Community Bancorp (NYCB) downgraded to Neutral from Buy at Guggenheim... El Paso Pipeline (EPB) downgraded to Trim from Hold at Tudor Pickering... Signature Bank (SBNY) downgraded to Neutral from Buy at Guggenheim... SunTrust (STI) downgraded at Morgan Stanley... Accenture (ACN) downgraded to Equal Weight from Overweight at Morgan Stanley... NetApp (NTAP) downgraded to Equal Weight from Overweight at Morgan Stanley... Teradata (TDC) downgraded to Underweight from Equal Weight at Morgan Stanley.
ChemoCentryx data promising, says Stifel After ChemoCentryx reported Phase II data for its CCX168 for the treatment of ANCA-associated renal vasculitis, Stifel thinks the results were compelling. However, the firm believes the trial had several shortcomings, and that clarification on appropriate endpoints and Phase 3 trial design are needed for a path forward for the drug. The firm keeps a $12 price target and Buy rating on the stock.